2d85d8b8-a590-4a3a-96f2-3f44b5a77032
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 46
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.200
- INTERFERON_ALPHA_RESPONSE+0.190
- ESTROGEN_RESPONSE_EARLY+0.160
- TNFA_SIGNALING_VIA_NFKB+0.160
- KRAS_SIGNALING_DN+0.100
- HEDGEHOG_SIGNALING+0.090
- MITOTIC_SPINDLE+0.090
- MYOGENESIS+0.090
- UV_RESPONSE_DN+0.090
- APICAL_JUNCTION+0.040
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.490
- FATTY_ACID_METABOLISM-0.410
- MTORC1_SIGNALING-0.370
- ADIPOGENESIS-0.310
- XENOBIOTIC_METABOLISM-0.310
- MYC_TARGETS_V1-0.290
- GLYCOLYSIS-0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.250
- CHOLESTEROL_HOMEOSTASIS-0.220
- DNA_REPAIR-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR13311176 | — | — | 0.820 |
| 2 | AUR-AER4-TTP1-A-1-0-R-A741-41 | — | D | 0.811 |
| 3 | SRR15030864 | — | — | 0.803 |
| 4 | 20040121.LumB | — | D | 0.795 |
| 5 | 4f0b1ac0-c503-4852-9a44-cb4231f4b17b | — | — | 0.793 |
| 6 | SRR4195673 | — | — | 0.790 |
| 7 | a83e78c0-8b1b-4576-aace-4bee1dee5046 | — | — | 0.787 |
| 8 | TCGA-LD-A7W6-01A-81R-A352-07 | — | A | 0.786 |
| 9 | de2e0c63-0c2d-43af-a006-7d84557a1c3c | — | — | 0.785 |
| 10 | MBCProject_2661_T2_RNA | — | A | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| MYOGENESIS | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.040 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.020 | Inavolisib | — uncovered |